Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Ajmer, Rajasthan, India.
Department of Biotechnology, School of Life Sciences, Central University of Rajasthan, Ajmer, Rajasthan, India.
J Biomol Struct Dyn. 2022 Jul;40(11):5189-5202. doi: 10.1080/07391102.2020.1869092. Epub 2021 Jan 6.
SARS-CoV-2 has been efficient in ensuring that many countries are brought to a standstill. With repercussions ranging from rampant mortality, fear, paranoia, and economic recession, the virus has brought together countries to look at possible therapeutic countermeasures. With prophylactic interventions possibly months away from being particularly effective, a slew of measures and possibilities concerning the design of vaccines are being worked upon. We attempted a structure-based approach utilizing a combination of epitope prediction servers and Molecular dynamic (MD) simulations to develop a multi-epitope-based subunit vaccine that involves the two subunits of the spike glycoprotein of SARS-CoV-2 (S1 and S2) coupled with a substantially effective chimeric adjuvant to create stable vaccine constructs. The designed constructs were evaluated based on their docking with Toll-Like Receptor (TLR) 4. Our findings provide an epitope-based peptide fragment that can be a potential candidate for the development of a vaccine against SARS-CoV-2. Recent experimental studies based on determining immunodominant regions across the spike glycoprotein of SARS-CoV-2 indicate the presence of the predicted epitopes included in this study.Communicated by Ramaswamy H. Sarma.
SARS-CoV-2 非常有效地使许多国家陷入停顿。该病毒导致了猖獗的死亡率、恐惧、偏执和经济衰退,促使各国寻求可能的治疗对策。由于预防干预措施可能需要数月时间才能特别有效,因此正在研究一系列关于疫苗设计的措施和可能性。我们尝试了一种基于结构的方法,利用表位预测服务器和分子动力学(MD)模拟的组合,开发了一种基于多表位的亚单位疫苗,该疫苗涉及 SARS-CoV-2 的两个刺突糖蛋白亚单位(S1 和 S2),并与一种有效的嵌合佐剂结合,以创建稳定的疫苗结构。根据与 Toll-Like Receptor(TLR)4 的对接情况对设计的结构进行了评估。我们的研究结果提供了一个基于表位的肽片段,可能成为开发针对 SARS-CoV-2 的疫苗的潜在候选物。最近基于确定 SARS-CoV-2 刺突糖蛋白上免疫优势区域的实验研究表明,本研究中包含的预测表位存在。由 Ramaswamy H. Sarma 传达。